Genmab | GEN - Operating Profit


Genmab reported DKK407M in Operating Profit for its fiscal quarter ending in June of 2026.





Operating Profit Change Date
Agios Pharmaceuticals USD -110.02M 11.55M Mar/2026
Almirall EUR 71.55M 41.32M Jun/2026
Amarin USD -2.26M 564K Dec/2025
Amgen USD 4.61B 777M Jun/2026
argenx SE USD 493M 99M Jun/2026
AstraZeneca USD 3.16B 3.95B Jun/2026
Bayer EUR 827M 2.7B Jun/2026
BioMarin Pharmaceutical USD 105.6M 24.04M Jun/2026
Demant DKK 2.12B 35M Jun/2026
Exelixis USD 248.41M 2.93M Jun/2026
Fresenius Medical Care EUR 537.27M 269.27M Jun/2026
Genmab DKK 407M 182M Jun/2026
GlaxoSmithKline GBP 2.6B 312M Jun/2026
GN Store Nord DKK 58M 126M Jun/2026
GRIFOLS EUR 329M 80M Jun/2026
Hikma Pharmaceutical USD 348M 161M Dec/2025
Insmed USD -101.31M 98.97M Jun/2026
Lakefront Biotherapeutics EUR -43.51M 20.19M Jun/2026
Lonza CHF 673M 243M Jun/2025
Merck EUR 1.1B 51M Jun/2026
Novartis USD 4.75B 515M Jun/2026
Regeneron Pharmaceuticals USD 1.42B 675.7M Jun/2026
Roche Holding CHF 11.46B 1.91B Jun/2026
Sanofi EUR 2.38B 449M Jun/2026
UCB EUR 1.29B 571M Dec/2025